BC Cancer Protocol Summary for Locally Advanced (Alternate) Head and Neck Cancer Using CISplatin During Radiation Therapy

**Protocol Code:** HNLAALTPRT

**Tumour Group:** Head and Neck

**Contact Physician:** Dr. Cheryl Ho

**ELIGIBILITY:**
- locally extensive head and neck cancer, squamous cell or sinonasal undifferentiated carcinoma at diagnosis, any age, ECOG status 0 or 1
- recurrent or metastatic squamous or sinonasal cancer, less than 70 years old (age 70-75 only if very good general condition), ECOG 0-2, good nutritional state
- normal renal function
- adequate marrow function
- no hearing impairment

**TESTS:**
- Baseline: CBC & diff, platelets, creatinine, sodium, potassium, serum calcium, serum magnesium, serum albumin, ALT, bilirubin
- Before each treatment: CBC & diff, creatinine

**PREMEDICATION:**
- Antiemetic protocol for moderately emetogenic chemotherapy (see SCNAUSEA)
  - For CISplatin doses greater than or equal to 50 mg, use antiemetic protocol for highly emetogenic chemotherapy (see SCNAUSEA)
  - Optional: For added hydration, may give D5W-1/2NS 1000 mL of with potassium chloride 20 mEq and magnesium sulfate 2 g over 1 hour on day 2 and/or day 4 with CISplatin.
TREATMENT:

Concurrent with radiation therapy

<table>
<thead>
<tr>
<th>Drug</th>
<th>Dose</th>
<th>BC Cancer Administration Guidelines</th>
</tr>
</thead>
<tbody>
<tr>
<td>CISplatin</td>
<td>25 mg/m²/day (days 1 to 4)</td>
<td>IV in NS 100 to 250 mL over 30 min (use NS 250 mL if greater than 60 mg)</td>
</tr>
</tbody>
</table>

- Radiation is given concurrently with CISplatin.
- For radiation delivered over 5-6 weeks: start day 1 and day 29
- For radiation delivered over 7 weeks: start day 1, day 22 and day 43
- Effort should be made to ensure radiation is given within 1-2 hours AFTER completion of the CISplatin infusion.
- At least one cycle of chemotherapy will be attempted concurrent with radiation therapy.

DOSE MODIFICATIONS:

1. Hematological

<table>
<thead>
<tr>
<th>ANC (x 10^9/L)</th>
<th>Platelets (x 10^9/L)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>greater than or equal to 1.5 and greater than 100</td>
<td>100%</td>
<td></td>
</tr>
</tbody>
</table>

If chemotherapy is to be given concurrently with radiation therapy, counts should be as above. If not, these dose reductions below apply.

<table>
<thead>
<tr>
<th>ANC (x 10^9/L)</th>
<th>Platelets (x 10^9/L)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>greater than or equal to 0.8 and greater than or equal to 100</td>
<td>100%</td>
<td></td>
</tr>
<tr>
<td>less than 0.8 or less than 100</td>
<td>50% dose reduction</td>
<td></td>
</tr>
</tbody>
</table>

2. Renal

<table>
<thead>
<tr>
<th>CrCl (By Cockcroft/Gault formula)</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>greater than or equal to 60 mL/min</td>
<td>100%</td>
</tr>
<tr>
<td>45 to 59 mL/min</td>
<td>50%</td>
</tr>
<tr>
<td>less than 45 mL/min</td>
<td>Delay x 1 week, then reassess</td>
</tr>
</tbody>
</table>

Cockcroft/Gault formula:

\[
\text{CrCl} = \frac{N \times (140 - \text{age}) \times \text{weight (kg)}}{\text{Serum Creatinine micromol/L}}
\]

Where N = 1.04 for females, and 1.23 for males.
3. Neurotoxicity:
- Tinnitus, mild high frequency hearing loss, and delayed peripheral neuropathy may occur secondary to CISplatin. The latter are generally reversible with time, though if the area of the eighth cranial nerve is to be radiated, hearing loss and tinnitus may be permanent. If clinically significant hearing loss or functionally significant peripheral neuropathy occurs, discontinue CISplatin only.

4. GI Toxicity:

<table>
<thead>
<tr>
<th>Symptom</th>
<th>Grade</th>
<th>Description</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nausea &amp; Vomiting</td>
<td>4</td>
<td>More than 10 episodes in 24 h or needs parenteral support, dehydration</td>
<td>If not controlled by antiemetics, give 80% dose or stop treatment</td>
</tr>
</tbody>
</table>

PRECAUTIONS:
1. **Nausea and vomiting** are common and patients should be treated with ondansetron and dexamethasone before and at least every 12 hours regularly during this treatment (see premedication section)
2. **Renal toxicity** may occur with a salt and water losing nephropathy. Patients should be encouraged to maintain good oral hydration.

Contact Dr. Cheryl Ho or tumour group delegate @ (604) 877-6000 or 1-800-663-3333 with any problems or questions regarding this treatment program.

References